Who
Eduardo Bruno Martins
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Sagimet Biosciences; SVP, Liver and Infectious Dise, Eiger BioPharmaceuticals.
In numbers
- Trades disclosed
- 18
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $140K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 23 Mar 2016
- Last trade
- 19 Feb 2026
- Last filed
- 20 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Feb 2026filed 20 Feb 2026 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —88,000 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —88,000 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Sold | $20K3,640 at $5.36 | filing |
| 10 Feb 2026filed 12 Feb 2026 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Sold | $20K3,640 at $5.36 | filing |
| 21 Jul 2025filed 23 Jul 2025 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Sold | $76K8,277 at $9.13 | filing |
| 6 Feb 2025filed 7 Feb 2025 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —138,000 at $0.00 | filing |
| 6 Feb 2025filed 7 Feb 2025 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 19 Jul 2024filed 23 Jul 2024 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Sold | $26K8,357 at $3.10 | filing |
| 17 Nov 2023filed 21 Nov 2023 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Code A | —89,570 at $0.00 | filing |
| 18 Jul 2023filed 20 Jul 2023 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —198,132 at $0.00 | filing |
| 18 Jul 2023filed 20 Jul 2023 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —198,132 at $0.00 | filing |
| 18 Jul 2023filed 20 Jul 2023 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —44,009 at $0.00 | filing |
| 18 Jul 2023filed 20 Jul 2023 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,009 at $0.00 | filing |
| 9 Mar 2017filed 14 Mar 2017 | Eiger BioPharmaceuticalsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 23 Mar 2016filed 15 Sep 2016 | Eiger BioPharmaceuticalsoption or derivative | SEC FORM 4 Code A | —65,216 at $0.00 | filing |
| 23 Mar 2016filed 28 Mar 2016 | Eiger BioPharmaceuticalsoption or derivative | SEC FORM 4 Code A | —65,216 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.